Pear Therapeutics, Inc.

Thimble Point Acquisition Corp, listed on Nasdaq under the ticker THMA and sponsored by Thimble Point Holdings LLC, completed its initial public offering in 2021 with a stated focus on healthcare and digital therapeutics. The blank-check company filed a Form 10-Q with the SEC on November 5, 2021, for the quarterly period ended September 30, 2021, at a point when a pending business combination with Pear Therapeutics, Inc., a developer of prescription digital therapeutics, was awaiting shareholder approval. The de-SPAC transaction subsequently closed in December 2021, with the combined company operating under the Pear Therapeutics name. Sign up at SpacDesk for full filing history, sponsor analytics, and deal-stage data on THMA and hundreds of other SPACs.